Skip to main content
Journal cover image

Long-term safety and efficacy of continuous intrathecal baclofen.

Publication ,  Journal Article
Campbell, WM; Ferrel, A; McLaughlin, JF; Grant, GA; Loeser, JD; Graubert, C; Bjornson, K
Published in: Dev Med Child Neurol
October 2002

Long-term continuous intrathecal baclofen (CITB) infusion is a treatment option used to manage otherwise intractable spasticity and is delivered via an implantable pump. The purpose of this single-center multidisciplinary review was to report on the long-term safety and efficacy of CITB in the treatment of 21 children with intractable severe spasticity of cerebral origin. Nineteen recipients had spastic quadriplegia and two had spastic diplegia. Seven recipients had level IV severity on the Gross Motor Functional Classification System and 14 had level V. Median age at implantation was 12 years (range 4 to 20). Fifteen recipients were male, 6 were female. Seventeen recipients were alive at the end of the follow-up period (31 to 78 months; mean 53, SD 4). The Ashworth scale showed a substantial decrease in spasticity in the upper and lower extremities at 6 months and at the most recent follow-up. The Gross Motor Function Measure and Pediatric Evaluation of Disability Inventory showed no functional change. Most treatment goals were at least partly achieved. Caregivers reported a reduction in use of oral medication for spasticity, and improvements in comfort, function, and ease of care. Caregiver satisfaction was high. During 80 recipient-years of pump operation, 153 treatment-associated adverse events occurred: 27 of these were device-related. There were four deaths unrelated to CITE, including one from acute pancreatitis. Our findings might assist in establishing patient selection criteria and treatment goals, improving patient follow-up, and monitoring adverse events.

Duke Scholars

Published In

Dev Med Child Neurol

DOI

ISSN

0012-1622

Publication Date

October 2002

Volume

44

Issue

10

Start / End Page

660 / 665

Location

England

Related Subject Headings

  • Treatment Outcome
  • Spinal Cord
  • Retrospective Studies
  • Pediatrics
  • Neurologic Examination
  • Muscle Spasticity
  • Male
  • Long-Term Care
  • Infusion Pumps, Implantable
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Campbell, W. M., Ferrel, A., McLaughlin, J. F., Grant, G. A., Loeser, J. D., Graubert, C., & Bjornson, K. (2002). Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol, 44(10), 660–665. https://doi.org/10.1017/s0012162201002729
Campbell, William M., Anne Ferrel, John F. McLaughlin, Gerald A. Grant, John D. Loeser, Catherine Graubert, and Kristie Bjornson. “Long-term safety and efficacy of continuous intrathecal baclofen.Dev Med Child Neurol 44, no. 10 (October 2002): 660–65. https://doi.org/10.1017/s0012162201002729.
Campbell WM, Ferrel A, McLaughlin JF, Grant GA, Loeser JD, Graubert C, et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol. 2002 Oct;44(10):660–5.
Campbell, William M., et al. “Long-term safety and efficacy of continuous intrathecal baclofen.Dev Med Child Neurol, vol. 44, no. 10, Oct. 2002, pp. 660–65. Pubmed, doi:10.1017/s0012162201002729.
Campbell WM, Ferrel A, McLaughlin JF, Grant GA, Loeser JD, Graubert C, Bjornson K. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol. 2002 Oct;44(10):660–665.
Journal cover image

Published In

Dev Med Child Neurol

DOI

ISSN

0012-1622

Publication Date

October 2002

Volume

44

Issue

10

Start / End Page

660 / 665

Location

England

Related Subject Headings

  • Treatment Outcome
  • Spinal Cord
  • Retrospective Studies
  • Pediatrics
  • Neurologic Examination
  • Muscle Spasticity
  • Male
  • Long-Term Care
  • Infusion Pumps, Implantable
  • Humans